Skip to contentpdufa.bio

Ciltacabtagene autoleucel

Page updated ·next FDA decision on the calendar ·Data as of Nov 19, 2026 12:24 AM ET

Ciltacabtagene autoleucel is a Legend Biotech Corp program in relapsed/refractory multiple myeloma (daratumumab-refractory subgroup). Its next catalyst is a Readout on Dec 12, 2026.

LEGN catalyst hub

All upcoming FDA decision dates on the 2026 PDUFA calendar

About this program

Indication under review: Relapsed/refractory multiple myeloma (daratumumab-refractory subgroup). Sponsor: Legend Biotech Corp (LEGN). We track 1 catalyst event for this program: 1 upcoming and 0 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.

Catalyst history

Readout · Dec 12, 2026LEGN

Questions

When is Ciltacabtagene autoleucel's next FDA decision or readout?

The next tracked catalyst for Ciltacabtagene autoleucel is a Readout on Dec 12, 2026.

What happened at Ciltacabtagene autoleucel's most recent FDA decision?

No FDA decision for Ciltacabtagene autoleucel is in our archive yet.

What is Ciltacabtagene autoleucel used for?

In our records Ciltacabtagene autoleucel is under review or in development for Relapsed/refractory multiple myeloma (daratumumab-refractory subgroup).

Who makes Ciltacabtagene autoleucel?

Legend Biotech Corp (LEGN).

Where does this data come from?

FDA announcements, sponsor press releases and SEC filings. Each FDA decision links its own page, which names its source or says plainly that it has none.